Literature DB >> 6802455

Decreased mineralization in hemodialysis patients after subtotal parathyroidectomy.

R S Weinstein.   

Abstract

Many hemodialysis patients undergo subtotal parathyroidectomy (sPTx) because of the complications of severe secondary hyperparathyroidism. In some patients, however, renal osteodystrophy fails to regress. In uremia, the high levels of circulating immunoreactive parathyroid hormone (iPTH) which accompany osteitis fibrosa are associated with accelerated bone formation. After sPTx, the fall in iPTH may decrease mineralization and increase osteoid formation. Bone histomorphometry, densitometry, and serum biochemical determinations were done in 20 patients on regular maintenance hemodialysis and after sPTx in 3 additional patients. Densitometry at the radial diaphysis was inversely related to osteoid volume so that low bone mineral content indicated excess osteoid. Elevated serum alkaline phosphatase activity was associated with osteitis fibrosa. Tetracycline double labels identified 5 patients with an increased rate of mineralization. Levels of iPTH and serum phosphorus were positively correlated to the mineralization rate. The fall in iPTH after sPTx was accompanied by a reduction in osteitis fibrosa and decreased mineralization. The nonosteoblastic osteoid became more abundant. After sPTx some hemodialysis patients may convert the osteitis fibrosa to a poorly treatable low turnover osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802455     DOI: 10.1007/BF02411202

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  15 in total

1.  MEASUREMENT OF BONE MINERAL IN VIVO: AN IMPROVED METHOD.

Authors:  J R CAMERON; J SORENSON
Journal:  Science       Date:  1963-10-11       Impact factor: 47.728

2.  The pathophysiology of bone and joint disease.

Authors:  S L Teitelbaum; P G Bullough
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

3.  Unique biosynthesis by kidney of a biological active vitamin D metabolite.

Authors:  D R Fraser; E Kodicek
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

4.  Quantitative histological studies on the pathogenesis of uremic bone disease.

Authors:  D J Sherrard; D J Baylink; J E Wergedal; N A Maloney
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

5.  Measurement of osteoid in bone biopsy.

Authors:  C G Woods; D B Morgan; C R Paterson; H H Gossmann
Journal:  J Pathol Bacteriol       Date:  1968-04

6.  Osteopenia and fractures occurring during maintenance hemodialysis. A new form of renal osteodystrophy.

Authors:  A M Parfitt; S G Massry; A C Winfield
Journal:  Clin Orthop Relat Res       Date:  1972-09       Impact factor: 4.176

7.  Do parathyroid hormone and 1,25-dithydroxyvitamin D modulate bone formation in uremia?

Authors:  S L Teitelbaum; M A Bergfeld; J Freitag; K A Hruska; E Slatopolsky
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

8.  Tetracycline double-labeling of iliac trabecular bone in 41 normal adults.

Authors:  F Melsen; L Mosekilde
Journal:  Calcif Tissue Res       Date:  1978-12-08

9.  Heterogeneity of adult hypophosphatasia. Report of severe and mild cases.

Authors:  R S Weinstein; M P Whyte
Journal:  Arch Intern Med       Date:  1981-05

10.  Radioimmunoassay of human parathyroid hormone in serum.

Authors:  C D Arnaud; H S Tsao; T Littledike
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

View more
  5 in total

1.  Stimulation of undermineralized matrix formation by 1,25 dihydroxyvitamin D3 in long bones of rats.

Authors:  J M Hock; M Gunness-Hey; J Poser; H Olson; N H Bell; L G Raisz
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

2.  Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3.

Authors:  M Gunness-Hey; J M Hock; I Gera; J Fonseca; J Poser; J Bevan; L G Raisz
Journal:  Calcif Tissue Int       Date:  1986-04       Impact factor: 4.333

3.  Model of experimental chronic osteomyelitis in rats.

Authors:  J P Rissing; T B Buxton; R S Weinstein; R K Shockley
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

4.  Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence.

Authors:  R L Jilka; R S Weinstein; K Takahashi; A M Parfitt; S C Manolagas
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

5.  Focal mineralization defect during disodium etidronate treatment of calcinosis.

Authors:  R S Weinstein
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.